Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Symbool: 002399.SZ
SHZ
9.37
CNYMarktprijs vandaag
-17.2720
Koers/Winst Verhouding
-0.4195
Koers/Winst Groei Verhouding
12.33B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10139.37 | 2265.8 | 3450.4 | 3925.4 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 1631.92 | 414.2 | 1311.6 | 981.2 | ||||||||||||||||||
balance-sheet.row.net-receivables | 6253.86 | 1528.6 | 1946.6 | 1985.5 | ||||||||||||||||||
balance-sheet.row.inventory | 30150.6 | 6654.1 | 6843.9 | 4707.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 857.6 | 155.4 | 148.7 | 151.2 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 47401.43 | 10603.9 | 12389.6 | 10769.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 10261.67 | 2634.2 | 2477.3 | 2537.2 | ||||||||||||||||||
balance-sheet.row.goodwill | 9504.81 | 2322.4 | 2351 | 2152.2 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 2153.33 | 493.2 | 571.7 | 586.7 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 11658.14 | 2815.6 | 2922.6 | 2738.9 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 8198.95 | 2514.9 | 1152.5 | 1636.7 | ||||||||||||||||||
balance-sheet.row.tax-assets | 753.39 | 320.5 | 139.6 | 121.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 2460.85 | 314.3 | 1732.5 | 1304.1 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 33333 | 8599.5 | 8424.6 | 8338.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.account-payables | 1374.71 | 302.2 | 427.4 | 385.8 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 14923.61 | 3662.4 | 4056.5 | 3299.9 | ||||||||||||||||||
balance-sheet.row.tax-payables | 525.27 | 157.2 | 141.8 | 158.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 8990.3 | 1810 | 2407.4 | 2354.3 | ||||||||||||||||||
Deferred Revenue Non Current | 127.65 | 30.4 | 32.5 | 16.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1232.54 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 3123.05 | 655.4 | 658 | 3.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 10620.06 | 2198 | 2830.8 | 2793.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 383.85 | 90.4 | 110.7 | 104 | ||||||||||||||||||
balance-sheet.row.total-liab | 31250.86 | 7184.2 | 8406.6 | 7584.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 5869.18 | 1467.3 | 1467.3 | 1467.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 14530.6 | 1543.2 | 4314.1 | 3647 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9077.94 | 1373.8 | 843.4 | 563.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 19614.97 | 7528.9 | 5686.1 | 5733.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 49092.69 | 11913.1 | 12310.9 | 11411.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.minority-interest | 360.05 | 75.2 | 96.7 | 112 | ||||||||||||||||||
balance-sheet.row.total-equity | 49452.73 | 11988.4 | 12407.6 | 11523.3 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 80734.43 | - | - | - | ||||||||||||||||||
Total Investments | 9830.87 | 2929.1 | 2464.1 | 2617.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 24004.33 | 5562.8 | 6463.9 | 5654.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 15496.87 | 3711.2 | 4325.1 | 2709.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -783.26 | -783.3 | 714.7 | 233.4 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 371.05 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 3.98 | -237.6 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -1332.4 | 43.3 | 0.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | -349.12 | -563.1 | -2311.3 | -1125.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 270.55 | 270.5 | -176.1 | 141.8 | ||||||||||||||||||
cash-flows.row.inventory | -619.67 | -619.7 | -2151.6 | -1520.2 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -213.9 | 59.7 | 423.9 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 548.74 | 3003.1 | 532.3 | 752.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 678.73 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 2.34 | -4.9 | 0 | 1.7 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -677.26 | -758.2 | -4482.7 | -2370.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1647.35 | 2349.3 | 4210.7 | 3305.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 694.02 | -0.1 | 744.2 | -22.9 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 1221.57 | 1141.2 | 249.8 | 719.9 | ||||||||||||||||||
cash-flows.row.debt-repayment | -5991.71 | -730.9 | -6036.3 | -3730.6 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -425.89 | -146.7 | -251 | -412.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 5207.43 | -325.4 | 6616.8 | 3642 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1210.17 | -1203 | 329.6 | -501.1 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 36.32 | 36.3 | 17.3 | -62.8 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 445.94 | -287.1 | -159.9 | 149.4 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6714.63 | 1851.6 | 1319.7 | 1479.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6268.69 | 2138.8 | 1479.6 | 1330.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 678.73 | 471.4 | -756.6 | -6.6 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 233.86 | 26.5 | -979 | -200.5 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5434.47 | 5421.7 | 7159.4 | 6365.2 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 3670.52 | 3746.3 | 4825 | 4332.1 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1763.95 | 1675.4 | 2334.4 | 2033 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 179.91 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 458.57 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 2128.44 | 1935.4 | 1211.9 | 1068.9 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 5798.96 | 5681.6 | 6036.9 | 5401 | ||||||||||||||||||
income-statement-row.row.interest-income | -39.52 | -39.5 | 54.1 | 54.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 241.34 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -433.09 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -674.43 | -259.9 | 1135.1 | 773.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -763.62 | -480.4 | 829.9 | 222.3 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | -126.17 | -126.2 | 115.2 | -11.1 | ||||||||||||||||||
income-statement-row.row.net-income | -783.26 | -783.3 | 727.4 | 240.8 |
Vaak gestelde vragen
Wat is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) totale activa?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) totale activa is 19203415131.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 2721572551.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.325.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.144.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.124.
Wat is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) nettowinst (netto-inkomen)?
De nettowinst is -783258039.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 5562816036.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 1935358054.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 1851642224.000.